Loading company…
Boston biotech founded in 2020 developing LINE-1 reverse transcriptase inhibitors aimed at diseases linked to the dark genome.
Rome Therapeutics, Inc. was founded in 2020 and is based in Boston, US. It develops therapies that target the dark genome, including proprietary LINE-1 reverse transcriptase inhibitors for conditions such as autoimmune disorders, cancer and neurodegenerative diseases. Its products are still preclinical, with its main markets in North America and Europe. The company raised USD 72.00 mn in Series B funding on June 6, 2023, from investors including Johnson & Johnson Innovation, Bristol-Myers Squibb and Andreessen Horowitz.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in